Possible role for TNF-alpha in early embryopathy associated with maternal diabetes in the rat

Diabetes ◽  
1995 ◽  
Vol 44 (5) ◽  
pp. 531-536 ◽  
Author(s):  
S. Pampfer ◽  
I. Vanderheyden ◽  
Y. D. Wuu ◽  
L. Baufays ◽  
O. Maillet ◽  
...  
Keyword(s):  
Development ◽  
1997 ◽  
Vol 124 (23) ◽  
pp. 4827-4836 ◽  
Author(s):  
S. Pampfer ◽  
I. Vanderheyden ◽  
J.E. McCracken ◽  
J. Vesela ◽  
R. De Hertogh

The morphogenetic function of the transient phase of cell death that occurs during blastocyst maturation is not known but it is thought that its regulation results from a delicate balance between survival and lethal signals in the uterine milieu. In this paper, we show that blastocysts from diabetic rats have a higher incidence of dead cells than control embryos. Differential lineage staining indicated that increased nuclear fragmentation occurred mainly in the inner cell mass. In addition, terminal transferase-mediated dUTP nick end labeling (TUNEL) demonstrated an increase in the incidence of non-fragmented DNA-damaged nuclei in these blastocysts. Analysis of the expression of clusterin, a gene associated with apoptosis, by quantitative reverse transcription-polymerase chain reaction detected an increase in the steady-state level of its transcripts in blastocysts from diabetic rats. In situ hybridization revealed that about half the cells identified as expressing clusterin mRNA exhibited signs of nuclear fragmentation. In vitro experiments demonstrated that high D-glucose increased nuclear fragmentation, TUNEL labeling and clusterin transcription. Tumor necrosis factor-alpha (TNF-alpha), a cytokine whose synthesis is up-regulated in the diabetic uterus, did not induce nuclear fragmentation nor clusterin expression but increased the incidence of TUNEL-positive nuclei. The data suggest that excessive cell death in the blastocyst, most probably resulting from the overstimulation of a basal suicidal program by such inducers as glucose and TNF-alpha, may be a contributing factor of the early embryopathy associated with maternal diabetes.


2010 ◽  
Vol 43 (17) ◽  
pp. 26-27
Author(s):  
DIANA MAHONEY
Keyword(s):  

Author(s):  
Alexander Hackel ◽  
Aleksandra Aksamit ◽  
Kirsten Bruderek ◽  
Stephan Lang ◽  
Sven Brandau

2011 ◽  
Vol 81 (6) ◽  
pp. 398-406 ◽  
Author(s):  
Akcam ◽  
Boyaci ◽  
Pirgon ◽  
Kaya ◽  
Uysal ◽  
...  

Objective: The aim of the study was to determine whether metformin or vitamin E treatment for six months is effective in reducing body weight, blood pressure, and also ameliorating insulin resistance, adiponectin, and tumor necrosis factor (TNF)-alpha in obese adolescents with non-alcoholic fatty liver disease (NAFLD). Methods: Sixty-seven obese adolescents with liver steatosis (age range, 9 - 17 years) were included in the study. The metformin group received an 850-mg dose of metformin daily and the vitamin E group received 400 U vitamin E /daily, in capsule form for 6 months, plus an individually tailored diet, exercise, and behavioral therapy. Results: After 6 months later, there was a significant decline in body mass index, and fasting insulin and homeostatic model assessment (HOMA) values in all three groups. Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study. There were no significant differences for changes of adiponectin, TNF-alpha, in all three groups after 6 months study. Conclusion: These data suggest that metformin treatment is more effective than dietary advice and vitamin E treatment in reducing insulin resistance, and also in ameliorating metabolic parameters such as fasting insulin and lipid levels, in obese adolescents having NAFLD.


Praxis ◽  
2011 ◽  
Vol 100 (4) ◽  
pp. 241-243
Author(s):  
Bandelow ◽  
Wiederkehr ◽  
Hasler

Ein 21-jähriger Patient mit einer Spondylitis ankylosans entwickelte unter der Behandlung mit Infliximab eine multifokale, axonale und demyelinisierende, simultan mehrere Nerven betreffende Neuropathie (Mononeuritis multiplex). Hierbei handelt es sich um eine weitere seltene Nebenwirkung einer Infliximab-Therapie am peripheren Nervensystem.


Sign in / Sign up

Export Citation Format

Share Document